ABSTRACT Background. Reexcision rates in patients undergoing breast-conserving surgery (BCS) for early-stage invasive breast cancer are highly variable. The Society of Surgical Oncology (SSO) and American Society for Radiation Oncology (ASTRO) published consensus guidelines to help standardize practice. We sought to determine reexcision rates before and after guideline adoption at our institution. Methods. We identified patients with stage I or II invasive breast cancer initially treated with BCS between June 1, 2013, and October 31, 2014. Margins were defined as positive (tumor on ink), close (B1 mm), or negative ([1 mm), and were recorded for both invasive cancer and ductal carcinoma-in situ (DCIS) components. Reexcision rates were quantified, characteristics were compared between groups, and multivariable logistic regression was performed. Conclusions. Overall reexcision rates declined significantly after guideline adoption. Close invasive margins were associated with higher rates of reexcision than negative invasive margins in both time periods; however, the effect diminished in the postguideline adoption period. Thus, we expect continued decline in reexcision rates as adherence to guidelines becomes more uniform.
ABSTRACT Background. Reexcision rates in patients undergoing breast-conserving surgery (BCS) for early-stage invasive breast cancer are highly variable. The Society of Surgical Oncology (SSO) and American Society for Radiation Oncology (ASTRO) published consensus guidelines to help standardize practice. We sought to determine reexcision rates before and after guideline adoption at our institution. Methods. We identified patients with stage I or II invasive breast cancer initially treated with BCS between June 1, 2013, and October 31, 2014. Margins were defined as positive (tumor on ink), close (B1 mm), or negative ([1 mm), and were recorded for both invasive cancer and ductal carcinoma-in situ (DCIS) components. Reexcision rates were quantified, characteristics were compared between groups, and multivariable logistic regression was performed. Results. A total of 1205 patients were identified, 504 before and 701 after the guideline adoption (January 1, 2014). Clinical and pathologic characteristics were similar between time periods. Reexcision rates significantly declined from 21. Conclusions. Overall reexcision rates declined significantly after guideline adoption. Close invasive margins were associated with higher rates of reexcision than negative invasive margins in both time periods; however, the effect diminished in the postguideline adoption period. Thus, we expect continued decline in reexcision rates as adherence to guidelines becomes more uniform.
Reexcision rates in patients undergoing breast-conserving surgery (BCS) for early-stage invasive cancer are highly variable. [1] [2] [3] [4] Until recently, there was no widely accepted standardized definition of an adequate margin, which contributed to significant practice variability in reexcision rates. [1] [2] [3] Reported rates vary widely (2-38 %), with variability found at the inter-and intrainstitution level as well as at the surgeon level, with variation present even among high-volume surgeons (11-20 %) . [2] [3] [4] On average, about 25 % of women require a second surgical procedure in an attempt to obtain a clear margin. 3, 4 There has been considerable debate and controversy regarding the definition of a negative margin, adequate margin widths, and indications for reexcision. In a recent population-based survey of surgeons on what defines an adequate margin for avoidance of reexcision in a unicentric T1b cancer, only 11 % of surgeons endorsed no ink on tumor. The majority of surgeons (42 %) required 1-2 mm, 28 % required C5 mm, and 19 % reported a need for a [1 cm margin. 1 In a large multicenter study, this wide variability led to two or more reexcisions in roughly 10 % of patients. 3 Multiple operations to obtain adequate margins add substantial psychological stress for the patient, increase health care costs, and have a potential cosmetic disadvantage. Additionally, approximately 10 % of women will opt for a completion mastectomy when presented with the need for reexcision. 3, 4 A prior failed attempt at breast conservation has also been shown to be an independent predictor of patient choice of bilateral mastectomy. 5 In response to the wide variability in reexcision rates, the Society of Surgical Oncology (SSO) and the American Society for Radiation Oncology (ASTRO) assembled a multidisciplinary expert panel to provide evidence based consensus guidelines. A meta-analysis of the relationship between margin width and ipsilateral breast tumor recurrence (IBTR) was performed from a systematic review of 33 studies including 28,162 patients. 6 This identified that a positive margin (ink on tumor) was associated with at least a twofold increase in IBTR, thus requiring reexcision. However, margins more widely clear than no ink on tumor did not further decrease the risk of IBTR obviating the need for further excision. This recommendation did not change for those omitting adjuvant systemic therapies, was not dependent on tumor biology or subtype, young patient age, tumor histology, or the presence of an extensive intraductal component (EIC). 6 Although these guidelines were published in March 2014, they were presented beginning in October 2013 after the consensus recommendations were finalized. Our breast disease management team adopted these recommendations in January 2014. Before release of these guidelines, the 12 surgeons in our group did not have a specific guideline margin standard. In this study, we analyzed the rates of reexcision before and after the adoption of the SSO-ASTRO margin guidelines and sought to identify factors associated with reexcision.
METHODS

Data Source
After study approval by the Memorial Sloan Kettering Cancer Center Institutional Review Board for Human Subjects Research, data were obtained from prospectively maintained institutional databases and electronic medical records. A cohort of patients treated with BCS for stage I or II invasive breast cancer, with planned subsequent whole breast irradiation, from June 1, 2013, through October 31, 2014 was identified. Patients who received neoadjuvant chemotherapy and those with bilateral invasive breast cancers, a personal history of prior breast cancer, or who had their index operation at another institution were excluded. Patients in this cohort did not receive intraoperative irradiation, partial-breast irradiation, or brachytherapy. Patients were grouped into 2 study periods; patients preceding the SSO-ASTRO guideline adoption (January 1, 2014), and those undergoing surgery after. This date of guideline adoption at our institution divided the cohort of BCS patients into a pre-(June 1, 2013-December 31, 2013) and postguideline (January 1, 2014-October 31, 2014) adoption time period.
Clinical and Pathologic Factors
Patient age, breast density, and histopathologic characteristics, including tumor size, histology, associated ductal carcinoma-in situ (DCIS), receptor subtype (estrogen receptor, progesterone receptor, HER-2/neu), nuclear grade, presence of lymphovascular invasion, EIC, and multifocality, were identified for each specimen. Final pathologic tumor size (pT), nodes (pN), and lymph node metastases (0, 1-3, C4) were also recorded. The receipt of adjuvant chemotherapy, endocrine and anti-HER-2 therapy, and whole-breast irradiation was recorded in a binary fashion (received/omitted).
During the study period, all surgeons at our institution routinely utilized a seed-localization technique for nonpalpable lesions and practiced a cavity-shave margin technique as previously described. [7] [8] [9] This technique does not orient the primary lumpectomy specimen but marks the new margin of each cavity shave margin, which is inked separately. If tumor is identified in this separately submitted margin, then a measurement is provided to the inked margin. These practices did not change during the study period. Margins were defined as positive if tumor was present at the inked margin, close if B1 mm, or negative if [1 mm or when there was no tumor in the separately submitted cavity margins. Margin status was recorded for invasive cancer and DCIS separately. Surgeon-level data were recorded to determine case volume and reexcision rates in the pre-and postguideline periods.
Statistical Analysis
Demographic as well as operative, detailed pathologic and outcome data were summarized by study period using median and range for continuous covariates, and frequency and percentage for categorical covariates. Comparison between the study period by Wilcoxon rank-sum tests and Fisher's exact tests was performed. Statistical analyses were performed by R version 3.1.1 (R Foundation, Vienna, Austria). Univariate logistic regression was used to identify factors associated with reexcision after initial BCS. Variables of interest were included in a multivariable logistic regression model in order to identify factors independently associated with reexcision, with interaction terms to evaluate whether the effect of margins on reexcision changed at the time of guideline adoption. p values of \0.05 were considered significant.
RESULTS
Between June 1, 2013, and October 31, 2014, 1205 patients were identified, 504 in the preguideline and 701 in the postguideline adoption groups. The overall cohort had a median age of 58 years and a tumor size of 1.2 cm; their disease was predominantly stage I (72 %), with the remainder being stage IIA (21 %) and IIB (7 %). All clinical and pathologic factors evaluated were similar between time periods except nuclear grade (Tables 1, 2 ). The postguideline group included a significantly higher proportion of patients with nuclear grade III tumors.
The reexcision rate declined from 21.4 to 15.1 % (p = 0.006) in the postguideline adoption time period, though the percentage of negative, close, and positive margins did not differ significantly (Table 3) . Of patients attempting BCS in the postguideline era, 85 % had a single procedure. Of those who required a reexcision, the vast majority required 1 reexcision, with only 0.9 % of initial BCS attempts requiring 2 reexcisions and \0.3 % requiring 3 or more. Conversion to mastectomy was a rare event, with less than 1 % of patients needing or electing for mastectomy after an initial attempt at BCS. We reviewed the reexcision rates for each margin category (negative, close, positive) for invasive and DCIS in both the pre-and postguidelines adoption study period, and we found that across all groups, the reexcision rate fell in the postguideline period (Table 4) .
We examined pathology characteristics (specifically the presence of EIC and multifocality) among patients who underwent reexcision in the postguideline period despite no positive margins for either the DCIS or invasive component. We found that among 37 patients with a close DCIS margin and a negative invasive margin, 21 had neither EIC nor multifocality. These data suggest ongoing uncertainty or concern regarding a close DCIS margin. Reexcision rates remained low in the final aspect of this study, and 3-month reexcision rates steadily declined (January-March 2014, 20.6 %; April-June 2014, 14.2 %; July-September 2014, 13.5 %). The final month of this data set (October 2014) had a reexcision rate of 8.0 %, indicating stability of guideline acceptance.
Surgeon-level data revealed that all surgeons were active in both time periods and performed similar relative volume of operations in the pre-and postguideline periods, indicating that differences in reexcision rates between the time periods were not due to surgeon variability. Individual surgeon (n = 12) reexcision rates for the postguideline period ranged from 6 to 25 %. Although the distribution of surgeon did not change over time, we performed a sensitivity analysis accounting for potential surgeon variability in decision making by adding a surgeon-level random effect to the models for reexcision. We found the effect of time period (pre-vs. postguideline) was not affected by whether or not a surgeon effect was included in the model. The odds ratio for time period in a univariable model was 0.65 (0.49, 0.88) without, and 0.64 (0.49, 0.87) with the surgeon effect.
Factors independently associated with reexcision by univariate and multivariate analysis are shown in Table 5 . Of the variables analyzed, 9 factors were significant by univariable analysis, including age, time period (after guideline adoption), close and positive invasive or DCIS margin, receptor subtype, EIC, lymphovascular invasion, multifocality, and presence of associated DCIS. Using these 9 factors, a multivariable model identified EIC, multifocality, positive and close DCIS margins, and positive and close invasive margins as independently associated with increased reexcisions. The postguideline time period was found to be independently associated with fewer reexcisions (odds ratio 0.53, 95 % confidence interval 0.32-0.88, p = 0.014) ( Table 5 ).
There was a significant association between the invasive margin and the DCIS margin (p B 0.001). A total of 154 cases were identified in which the margin was negative for invasive cancer but close for DCIS. The reexcision rate in this subgroup in the postguideline adoption group trended toward significantly fewer reexcisions (p = 0.078), indicating acceptance of the consensus guideline for invasive cancer even in the setting of isolated close margins of DCIS.
In a model run with interaction terms between margin status and time period, close invasive margin was associated with 13.0 times the odds of reexcision before guideline adoption, which decreased to 4.2 after adoption; however, this difference did not reach significance (p = 0.331). Similarly, a close DCIS margin was associated with 68.4 times the odds of reexcision for DCIS before guideline adoption, decreasing to 24.6 after adoption (p = 0.205). Because neither was found to be significantly different, interaction terms were omitted in the final model for simplicity.
DISCUSSION
The SSO-ASTRO margin guidelines were developed in response to a lack of consensus regarding the definition of a negative margin as well as highly variable rates of reexcision among surgeons. In this study, we examined our reexcision rates in the time period immediately before and after adoption of the SSO-ASTRO margin guidelines. In our large cohort of 1205 consecutive BCS patients, we noted a significant decline in overall reexcision rates from 21.4 % (June-December 2013) to 15.1 % (January-October 2014). The time period after the guideline adoption was independently associated with fewer reexcisions, with roughly half the odds of requiring a reexcision in the postadoption time period. This suggests surgeon adoption of the guideline and a change in practice pattern, with fewer return trips to the operating room for close but negative margins.
Since publication of the SSO-ASTRO guidelines, an American Society of Breast Surgeons (ASBrS) survey was performed presenting a sample of clinical scenarios and querying the likelihood of reexcision. 10 Overall, they reported significant familiarity with the consensus guidelines; however, wide acceptance remains uncertain. In noncontroversial examples, such as a 2 mm margin, with a favorable tumor subtype, 95 % of surgeons responded they would never or infrequently reexcise the margin. However, highly variable responses were obtained for more complex cases, such as those with margins closer than 1 mm, multiple close margins, presence of extensive DCIS, or more aggressive subtypes; these likely reflect a hesitation to adopt the guidelines as more complex decision-making becomes necessary. 10 Similarly, in our series, we noted a close invasive margin was associated with a higher reexcision rate than a negative invasive margin; however, the effect of close versus negative was smaller in the postguideline adoption period, demonstrating a greater adoption of the guidelines. We noted a similar finding with a close versus negative DCIS margin. A close DCIS margin increased the chance of reexcision more than a close invasive margin (odds ratio 38.3 vs. 6.35). These data suggest ongoing uncertainty about the optimal margin for DCIS, as was also seen in the ASBrS survey. However, the SSO-ASTRO guidelines specifically note that reexcision is appropriate for negative margins in clinical circumstances where the likelihood of a heavy residual tumor burden is high, so some of this variation is reflective of reasonable clinical judgment.
Other factors independently associated with reexcision in our series were EIC and multifocality. In the SSO-ASTRO guidelines, EIC was highlighted as a cautionary area, as it reflects a large DCIS burden and may be associated with residual DCIS after BCS. Historical data in studies performed in an era without margin assessment found a significantly higher rate of IBTR with EIC-associated invasive breast cancer.
11,12
However, more contemporary studies do not note an increase in IBTR with EIC-associated invasive cancers when margins are negative, and thus no ink on tumor remains a negative margin even in the presence of EIC. 13 While we know a positive margin is associated with at least a doubling of the risk of an in-breast tumor recurrence (IBTR), increasingly wider margins have not been shown to reduce IBTR. 14, 15 This principle holds true even in the triple-negative subset known to have one of the highest rates of local recurrence. A recent study evaluated the impact of margin width on IBTR for triple-negative breast cancer and found margin width [2 mm was not associated with reduced rates of IBTR when compared to smaller margins. 16 Notably, the IBTR for this subset was remarkably low, with only 5 % of those with \2 mm margins having an IBTR at 60 months of median follow-up. These extremely low rates of recurrence are likely attributed to advancements in radiation and systemic therapies providing improved local control. There is a growing body of literature supporting the concept that bad tumor biology is the driver of recurrence, not tumor left behind, and larger surgical excisions do not alter this factor. [17] [18] [19] In our study, we found triple-negative histology to be associated with reexcision on a univariate analysis, but not to be significant on multivariable analysis again supporting no ink on tumor as defining a negative margin regardless of receptor subtype.
We found a very low rate of mastectomy after BCS, with only 8 patients proceeding with completion mastectomy after an initial attempt at BCS (\1 %). One possible explanation for our low rate of mastectomy after BCS may be because only 1 % of patients required 2 or more reexcisions, allowing fewer opportunities for patients to reconsider mastectomy as a treatment option.
Our rate of conversion to mastectomy is low compared to other published reports. For example, in a large published series of 1468 patients undergoing BCS, 11.9 % of patients proceeded to mastectomy. 4 Another recent study by Isaacs et al. also reported more than 10 % of patients proceeded to mastectomy after initial BCS attempt. 20 That study included 89,448 patients attempting BCS in New York State and reported highly variable reexcision rates of 0-100 %. The majority of the surgeons in this study were low-volume surgeons, with 90.8 % of surgeons performing a mean of less than 14 primary cases per year. Low-volume surgeons were independently associated with higher reoperation rates, had an unadjusted reoperation rate of 35.2 %, and had a 50 % higher risk for reexcision compared to higher-volume surgeons. 20 However, the commentary by Nag and Hwang appropriately highlighted the multiple elements that contribute to this variability beyond the surgeon alone, specifically including intraoperative radiographic evaluation, pathologic processing and assessment, and proficiency of preoperative breast radiologists' localization. 21 Our study has some notable strengths and limitations. This is a very large data set including over 1200 BCS cases from a single institution. Advantages include a uniform surgical technique using the cavity-shave method by all 12 surgeons, the consistency of the pathologic analysis, and a practice agreement to adopt the guidelines. As a retrospective series, this study is limited in its ability to decipher information regarding surgeon and patient-level decision making. We did not collect information regarding intraoperative specimen radiographs, postexcision mammography, magnetic resonance imaging, and how these factors may influence the surgeon's recommendations regarding reexcision.
In summary, after adoption of the SSO-ASTRO guidelines, reexcision rates fell significantly, from 21.4 to 15.1 %. We anticipate further reduction in reexcision rates with closer adherence to guidelines and expanded comfort level. We also await further guidelines regarding DCIS that will help address the need for reexcision in the group where the invasive component margin is negative and DCIS is close. Follow-up studies are indicated to follow long-term outcomes after the widespread implementation of these guidelines. Factors not associated with reexcision (univariable associations): method of detection, breast density, tumor size, tumor histology, nuclear grade, pathologic tumor or nodal classification, number of positive nodes, pathologic stage, and planned chemotherapy, radiotherapy, or endocrine therapy OR odds ratio, CI confidence interval, DCIS ductal carcinoma-in situ, ER estrogen receptor, PR progesterone receptor * Statistically significant a n = 1147
